Friday, 21 Sep 2018

RA/Inflammatory arthritis

Datesort ascending Type Title Save
29 Apr 2018 Social RheumNow week in Review is up - FDA Showdown! Listen to the podcast on iTunes or here https://t.co/Kp5tcuaR2B or watch the video https://t.co/YjU5DgK0OH
24 Apr 2018 News FDA Review: Take Two for Baricitinib
23 Apr 2018 Social FDA Arthritis advisory panel voting on baricitinib safety was 9-6 in favor of 2mg and was 11-4 against the safety of 4 mg
23 Apr 2018 Social FDA Arthritis panel on Baricitinib approval in RA votes 10-5 in favor of 2 mg dose but voted 10-5 Against baricitinib 4 mg dose. Concerns about safety of 4 mg dose, esp VTE, thrombophilia
23 Apr 2018 Social FDA Arthritis advisory panel voting in progress. Early votes unanimously in favor of baricitinib efficacy at 4 mg (15-0) or 2mg(14-1 unfavorably)
22 Apr 2018 Social RT @NatRevRheumatol: #TrendingNow Chester Oddis & Rohit Aggarwal discuss the treatment of myositis https://t.co/dcPx9bY1DX #myositis #treat…
20 Apr 2018 Social RT @RheumNow: RHEUMATOLOGIST VOTE: Active RA, SJC=5, fails 1st TNF inhibitor, which is your next choice:
20 Apr 2018 Social Fostamatinib, a spleen tyrosine kinase (Syk)inhibitor, that failed in #RA, has been FDA approved for use in adult with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug will be called Tavalisse. https://t.co/uQVpV6NioD
19 Apr 2018 Social Study of 1181 Systemic Sclerosis pts finds 3.4% w/ hx of VTE events= VTE incidence of 2.7 per 1000 pt-yrs (equal to general population). Risk factors for VTE were PAH, peripheral arterial disease, Scl-70+, anticardiolipin Abs (OR 2.45-5.7) https://t.co/AgBb7tGvGh
19 Apr 2018 Social RHEUMATOLOGIST VOTE: Active RA, SJC=5, fails 1st TNF inhibitor, which is your next choice:
19 Apr 2018 News Shared Epitope - Smoking Pathogenic Link Clarified
17 Apr 2018 News Kineret Approved for Still's Disease in EU
16 Apr 2018 Social 2996 HIV+ patients on HRT finds 113 w/ Rheumatic disease, lead by AVN 39 (1.3%), psoriasis 28 (1%), RA 7, PsA 6, & SLE 6pts. HIV Males 1.7 times more likely to have a rheum Dz. Hep C incr the risk of RD. RD Risk in HIV+ appears same as gen population. https://t.co/32PiLEeKgI
13 Apr 2018 News Mayo and UAB Awarded $1 million Grant for Patient Research
12 Apr 2018 Social In a historical prospective cohort study, PPI use in RA (1:4) was associated with a doubling of risk for acute kidney injury (HZ 2.30: 1.26-4.20) but was only 2.2 AKI per 1000PY in RA/PPI+ vs 0.9/1000PY in RA without PPI. Thus depends on need for PPI https://t.co/TxqjAR7Y5Y
09 Apr 2018 News Defining Refractory Rheumatoid Arthritis
09 Apr 2018 Social New RheumNow Survey on the risk of Venous-Thromboembolic Events in RA - Rheums vote here: (VTE is usually due to?) https://t.co/rmilEeZthL
09 Apr 2018 Social Abbvie announces results of its JAK inhibitor upadacitinib ouperforming adalimumab with ACR20 71%, ACR50 of 45%, 29 DAS remission, LDAS 45% at week 12 https://t.co/4bQ6FOkLhc
08 Apr 2018 Social 56 myositis patients with anti‐NXP‐2 autoantibodies (18 with and 38 without calcinosis) showed that NXP‐2 Ab levels correlate w/ disease activity, espcially in those without calcinosis; suggesting calcinosis defines 2 phenotypes. https://t.co/oxtpwUbtJv
06 Apr 2018 Social RheumNow Wk in Review is up! The Temporal Artery Biopsy Letdown! Listen https://t.co/HXSTSfAwlX or watch on the website https://t.co/WN6VYQwSQp